Takeda Europe News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Takeda europe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Takeda Europe Today - Breaking & Trending Today
Takeda Pharmaceutical Company Limited: European Patient Survey finds Crohn's Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn's Disease Patients without Perianal Fistulas finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board BARCELONA, Spain, Jan. 07, 2021 Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Mr. Di Nepi has accumulated nearly 40 years of global experience in the Healthcare sector. His career started with 16 years at McKinsey & Company, where he was a Partner and Core Leadership member of the Global Pharmaceutical Practice, followed by 11 years at ....
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda’s Europe and Canada Business Unit. This divestment agreement was first announced in September 2020. The divested portfolio is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories that includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. In line with Takeda’s long-term growth strategy, these products, while addressing key patient needs in these countries, are outside of Takeda’s five core business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and N ....
KKR Appoints Giacomo Di Nepi as Senior Advisor for Private Equity in Europe LONDON (Business Wire) KKR, a leading global investment firm, today announced the appointment of Giacomo Di Nepi as a Senior Advisor, effective immediately. In his role, Mr. Di Nepi will advise KKR on Healthcare investment opportunities and support existing portfolio companies. Mr. Di Nepi brings nearly 40 years of global experience in the Healthcare sector. He began his career at McKinsey, followed by 11 years at Novartis where he held a number of executive roles, including CEO of Novartis Italy and Global Head of the Infectious Diseases, Transplantation, and Immunology Business Unit and member of the Global Pharma Executive Committee. He also served as CEO of Takeda Europe. In 2009 he launched the European operations of Intermune near Basel, with the company growing exponentially under his leadership until a USD 8.3bn exit to Roche in 2015. He subsequently became CEO of Polyphor, a Swiss biopha ....
(2) Appointment further demonstrates focus on expanding the firm s presence in the Healthcare sector KKR, a leading global investment firm, today announced the appointment of Giacomo Di Nepi as a Senior Advisor, effective immediately. In his role, Mr. Di Nepi will advise KKR on Healthcare investment opportunities and support existing portfolio companies. Mr. Di Nepi brings nearly 40 years of global experience in the Healthcare sector. He began his career at McKinsey, followed by 11 years at Novartis where he held a number of executive roles, including CEO of Novartis Italy and Global Head of the Infectious Diseases, Transplantation, and Immunology Business Unit and member of the Global Pharma Executive Committee. He also served as CEO of Takeda Europe. In 2009 he launched the European operations of Intermune near Basel, with the company growing exponentially under his leadership until a USD 8.3bn exit to Roche in 2015. He subsequently became CEO of Polyphor, a Swiss b ....